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Background: Since artesunate (ART) became a vital component of artemisinin (ARM)-based combination therapies
for the treatment for malaria, counterfeit ART drugs have spread in regions of Southeast Asia and Africa. The
consumption of counterfeit ART drugs has resulted in the death of many patients. Thus, evaluating the quality of
ART drugs is needed. There are several methods for quantitating the ART content in tablets, the most common
being a high-performance liquid chromatography. However, that method is hampered by the need for expensive
equipment and a rather time-consuming process of extraction. By contrast, enzyme-linked immunosorbent assays
(ELISAs) are faster and much less expensive, and they require less sample preparation than the above method. The
objective of the present study was to establish a simple and specific direct competitive ELISA for the determination
of ART concentrations using an anti-ART polyclonal antibody (pAb).
Results: Anti-ART pAb was raised in mice, and ART-horseradish peroxidase (HRP) conjugate was produced. A direct
competitive ELISA was performed by simultaneously incubating ART and the ART-HRP conjugate with the anti-ART
pAb over a second antibody. Subsequently, the enzyme activity of the remaining ART-HRP conjugate was
measured. The intra- and inter-assay coefficients of variation of the ELISA were less than 10 % in the range of 0.3 to
30 ng/ml with a detection limit of 0.1 ng/ml. The cross-reactivities of the anti-ART pAb with ARM and
dihydroartemisinin were 0.12 and 0.04 %, respectively, and those with other antimalarial drugs were negligible.
Furthermore, the recovery of 10 or 50 ng/ml ART added to the drug tablet solutions containing an expected
amount of 10 ng/ml was estimated by the ELISA. The recovery of the ART amount ranged between 98 and 106 %,
with coefficient variations of less than 7.0 %.
Conclusions: The present ELISA is a simple and specific method for the determination of ART concentrations. Thus,
this ELISA can be used to identify ART counterfeits and substandard drugs and to quantify the ART drugs.
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Since WHO recommended artemisinin (ARM)-based
combination therapies (ACTs) as the first-line treatment
for malaria [1], artesunate (ART) has been a vital com-
ponent of ACTs and widely used in the treatment of
malaria. On the other hand, the massive demand for and
relatively high retail price of ART have promoted theCorrespondence: ymitsui@nagasaki-u.ac.jp
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Asia and Africa [2–4].
ART is currently the target of an extremely sophisti-
cated and prolific counterfeit drug trade, both in terms
of ART tablets and packaging [5–7], the latter closely re-
sembling that of the authentic product. The counterfeit
or substandard ART drugs can cause therapeutic failure
and death in malaria patients and increase the risk of
selecting and spreading of malarial parasites resistant to
artemisinin derivatives [7, 8].le is distributed under the terms of the Creative Commons Attribution 4.0
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et al. developed and validated a rapid and inexpensive
colorimetric Fast Red TR dye test to distinguish counter-
feit ART from genuine tablets [9]. However, counterfeiters
sometimes include subtherapeutic amounts of ART in the
tablets in order to evade the rapid colorimetric tests cur-
rently used to detect counterfeits [7, 10, 11].
Generally, high-performance liquid chromatography
(HPLC) is the standard analytical method to assess a
drug quantitatively and accurately differentiate between
genuine and counterfeit ART drugs [12, 13]. However,
the procedure involves a time-consuming extraction and
is unsuitable for the measurement of large sample num-
bers. In addition, resources to purchase and maintain
such expensive equipment are not always available in
many tropical and subtropical countries. By contrast,
enzyme-linked immunosorbent assays (ELISAs) are gen-
erally very simple and specific methods for quantitative
measurements of drugs. Ferreira and Janick and Tanaka
et al. produced polyclonal antibodies (pAbs) and mono-
clonal antibodies (mAbs) to ART [14, 15], respectively,
and developed an indirect competitive ELISA for detec-
tion of ARM in botanical samples. Subsequently, Wang
et al. developed an indirect competitive ELISA of ART
using anti-ART mAb produced by He et al. and applied
the assay for the quantification of ART tablets [16, 17].
The assay might lack adequate specificity to ART, how-
ever, because of the cross-reactivities of the anti-ART
mAb with ARM (15.5 %) and dihydroartemisinin (DHA)
(8.8 %). The objective of the present study was to pro-
duce an anti-ART pAb specific for ART and to develop a
simple and specific direct competitive ELISA for detect-
ing ART amounts using the anti-ART pAb.
The present study was conducted for (1) the produc-
tion of the anti-ART pAbs specific to ART in mice, (2)
the establishment of a direct competitive ELISA for
ART, and (3) the assessment of the recovery of ART




ART and DHA were obtained from LKT Laboratories,
Inc. (St. Paul, MN, USA) and Toronto Research Chemicals
Inc. (North York, ON, Canada), respectively. Artesunat®
tablets (Traphaco Joint Stock Company, Hanoi, Vietnam)
were purchased from a local pharmacy in Hanoi, Vietnam.
1-Ethyl-3(3-diethylaminopropyl) carbodiimide hydro-
chloride (EDC) was purchased from Dojindo Laboratories
(Kumamoto, Japan). Horseradish peroxidase (HRP) was
obtained from Roche Diagnostics GmbH (Mannheim,
Germany). Bovine serum albumin (BSA), ARM, chloro-
quine (CQ)·2H3PO4, primaquine (PQ)·2H3PO4, meflo-
quine (MQ)·HCl, pyrimethamine (PY), and sodiumsulfadiazine (SF) were purchased from Sigma (St. Louis,
MO, USA). Quinine (QN) and 3,3′,5,5′-tetramethylbenzi-
dine (TMB) were obtained from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan). Amodiaquine (AQ)·2HCl
and goat anti-mouse IgG(Fc) antibody were purchased
from MP Biomedicals Inc. (Fountain Parkway Solon, OH,
USA). All other chemicals and solvents were reagent
grade or chemically pure.
Preparation of ART-BSA conjugate used as an
immunogen
The ART-BSA conjugate used as an immunogen was
prepared according to a modified N-hydroxysuccinimide
(NHS) ester method [18]. EDC (5 mg) and NHS (5 mg)
were added to a solution of ART (5 mg) dissolved in
0.3 ml of a solution of dimethylformamide (DMF)/0.1 M
sodium phosphate buffer solution (PB), pH 7.0 (2/1, v/v),
and then stirred for 1.5 h at room temperature (rt). The
result was slowly added to a solution of BSA (5 mg) dis-
solved in 0.3 ml of 0.1 M PB (pH 7.2) and vigorously
stirred for 1.5 at rt. The conjugate was then dialyzed
against 2 l of phosphate-buffered saline (PBS) (137 mM
NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM KH2PO4,
pH 7.4) and stored at −30 °C.
Preparation of an anti-ART polyclonal antiserum
Five female ICR mice aged 6 weeks (Clea Japan, Inc.,
Tokyo, Japan) were injected intraperitoneally with 20 μl
of a saline solution containing 20 μg of ART-BSA conju-
gate emulsified with 180 μl of Freund’s complete adju-
vant at weeks 0, 4, and 6. At week 8, the blood was
drawn from each mouse by heart puncture and pooled,
and the serum was separated by centrifugation and
stored at −80 °C until use.
Preparation of ART-HRP conjugate
The ART-HRP conjugate was also prepared by the NHS
method. EDC (10 mg) and NHS (5 mg) were added to a
solution of ART (10 mg) dissolved in a 0.3 ml of a solu-
tion of DMF/PB (pH 7.0) (2/1, v/v) and then stirred for
1 h at rt. The result was slowly added to a solution of
HRP (5 mg) dissolved in 0.35 ml of PB (pH 7.2) and vig-
orously stirred for 3 h at rt. After centrifugation at 200g
for 2 min, the supernatant solution was dialyzed against
2 l PBS overnight at rt. The final solution was stored
with 20 % ethylene glycol at −80 °C.
A direct competitive ELISA for the determination of ART
concentrations using an anti-ART polyclonal antiserum
As shown in Fig. 1, the assay was carried out in the fol-
lowing steps. Step 1: each well of a 96-well microtiter
plate (Immunoplate Maxisorp, Nunc, Roskilde,
Denmark) was coated with 200 μl of goat anti-mouse
IgG(Fc) antibody (3.5 μg/ml) diluted with 0.1 M sodium
Fig. 1 Schematic illustration for the direct competitive ELISA of artesunate
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bated for 1 h at rt, and the antibody solution was dis-
carded. Step 2: 300 μl of PBS containing 1 % BSA was
added to each well, and the plate was incubated for 1 h
at rt. The blocking solution was discarded. Step 3: after
washing with 300 μl of PBS containing 0.05 % Tween 20
(PBS-T), 100 μl of standard ART or tested sample di-
luted in PBS containing 0.1 % BSA (BSA-PBS), 50 μl of
1:20,000-diluted stored solution of ART-HRP conjugate
in BSA-PBS, and 50 μl of 1:10,000-diluted anti-ART anti-
serum in BSA-PBS were added to each well. Subse-
quently, the incubation was continued overnight at 4 °C.
The wells were then washed three times with 300 μl of
PBS-T. Step 4: 200 μl of a substrate solution (20 ml of
0.1 M sodium acetate buffer (pH 5.0) supplemented with
200 μl of dimethyl sulfoxide containing 10 mg/ml TMB
and 10 μl of 30 % hydrogen peroxide) was added to each
well and incubated for 1 h at rt. Step 5: the reaction was
terminated by adding 100 μl of 1 M phosphoric acid,
and the absorbance was measured at 450 nm with a mi-
croplate reader (Multiskan Bichromatic; Labsystems,
Helsinki, Finland).
Specificity of anti-ART pAb to ART-related antimalarial
drugs
Cross-reactivity (CR) of the anti-ART pAb to ART-
related antimalarial drugs was tested by the competitive
ELISA. ART, ARM, DHA, QN, CQ, PQ, MQ, AQ, PY,
and SF were used as an inhibitor replacing ART. Each
drug was dissolved in BSA-PBS or BSA-PBS containing
0.5 % DMF to a concentration of 10 μg/ml and diluted
serially in BSA-PBS. Concentrations of these solutions
were estimated using the competitive ELISA. CRs of
anti-ART pAb for ART-related antimalarial drugs weredetermined by dividing the 50 % inhibitory concentra-
tion (IC50) of ART by the IC50 values of each antimalar-
ial drug and expressed as a percentage.
Intra- and inter-assays
In intra-assay, five replicate samples containing ART at
six different concentrations of 0.1, 0.3, 1.0, 3.0, 10, and
30 ng/ml were prepared and amounts of the ART in
each sample were estimated using the described com-
petitive ELISA procedure. Mean and standard deviation
(SD) in six different concentrations were calculated,
thereafter. The coefficient of variation (CV) was calcu-
lated using formula: 100 × SD/mean. Furthermore, the
recovery was calculated using formula: 100 ×mean esti-
mated amounts/added amounts. In inter-assay, other five
replicate samples containing ART at six different con-
centrations of 0.1, 0.3, 1.0, 3.0, 10, and 30 ng/ml were
also prepared 1 week later, and amounts of the ART in
each sample were estimated using the competitive
ELISA. After adding data of the five replicates in the
intra-assay, amounts of ART estimated in 10 replicate
samples were combined, and mean, SD, CV, and the re-
covery were calculated.
Recovery of ART added to tablet sample solutions
estimated by the ELISA
One tablet of Artesunat® (each tablet was expected to
contain 50 mg ART; one tablet weighed around 260 mg)
was crushed with a mortar and pestle. One twentieth of
the crushed powder (expected to contain 2.5 mg of ac-
tive ART) was weighed accurately and suspended in
1 ml of methanol/deionized water (DW) (1/1, v/v). To a
1.5-ml test tube, 100 μl of the suspended solution and 0,
100, or 500 μl stock solution of 2.5 mg/ml ART
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adjusted to 1 ml with 0.1 % BSA-PBS. The solution was
further diluted up to 25,000-fold with 0.1 % BSA-PBS at
final concentrations of 0, 10, or 50 ng/ml of added ART.
The concentrations of ART were estimated by the direct
competitive ELISA as described above.
In intra-assay, six replicate samples of tablet sample
solution alone, supplemented with 10 or 50 ng/ml ART,
were prepared and amounts of ART in each replicate
samples were estimated using the described competitive
ELISA. Mean and SD of amounts of ART estimated in
each replicate samples were calculated, thereafter. The
CV was calculated using formula: 100 × SD/mean. Fur-
thermore, the recovery was calculated using formula:
100 × (mean ART amounts estimated −mean estimated
ART amounts in a tablet sample solution alone)/ART
amounts added. In inter-assay, other six replicate sam-
ples of tablet sample solution alone, supplemented with
10 or 50 ng/ml ART, were also prepared 1 week later,
and amounts of ART in each replicate samples were esti-
mated using the ELISA. After adding data of the six rep-
licates in the intra-assay, amounts of ART estimated in
12 replicate samples were combined, and mean, SD, CV,
and the recovery were calculated.
Results
Standard curve of the direct competitive ELISA for ART
The standard curve of the direct competitive ELISA for
ART is shown in Fig. 2. The dose response range yielded
was between 0.03 and 100 ng/ml.
Specificity of the anti-ART pAb
Specificities of the anti-ART pAbs with ART derivatives
and current antimalarial drugs are shown in Table 1.Fig. 2 Standard curve for the direct completive ELISA of artesunate. Each pThe cross-reactivities of the anti-ART pAbs with ARM
and DHA were 0.12 and 0.04 %, respectively, whereas
those with all other antimalarial drugs were less than
0.023 %.
Precision and accuracy of the direct competitive ELISA of
ART
The precision and accuracy of the ELISA was examined
at six different ART concentrations over the range of
0.1–30 ng/ml (Table 2). The recovery of added ART
ranged between 97 and 106 % in the intra- and inter-
assays. The coefficients of variation were less than 7 %
in the range of 0.3–30 ng/ml. The detection limit of the
ELISA was 0.1 ng/ml.
Recovery of ART added to a tablet sample solution
estimated by the ELISA
The recovery of ART added to ART tablet sample solu-
tions is shown in Table 3. The estimated concentration of
active ART in the tablet sample solutions was 7.6 ng/ml in
intra- and inter-assays. Since a concentration of 10 ng/ml
was equivalent to 50 mg per one tablet, the estimated
amount of ART in the tablet samples was 38.0 mg (=50 ×
7.6/10, active ART in the tablet 76 %). When 10 or 50 ng/
ml ART was added to the tablet sample solutions, the re-
covery of the ART ranged between 98 and 106 % with a
coefficient of variation of less than 7 % in the intra- and
inter-assays.Discussion
A direct competitive ELISA of diethylcarbamazine
(DEC) was previously reported to be more simple, sensi-
tive, and reproductive than an indirect competitiveoint is the mean ± standard deviation of six assays
Table 1 Cross-reactivities of anti-artesunate (ART) polyclonal

















aTest compound solutions contained 0.5 % dimethylformamide at a
concentration of 104 ng/ml
bConcentrations of test compounds were expressed as free base
cCross-reactivity of anti-ART antibodies for ART-related antimalarial drugs was
determined by dividing the 50 % inhibitory concentration (IC50) of ART by the
IC50 values of each antimalarial drug and expressed as a percentage
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attempt to develop a direct competitive ELISA of ART.
As a prerequisite for the development of the direct
competitive ELISA of ART, ART-BSA and ART-HRP
conjugates were required. To obtain ART-BSA conjugate
as the immunogen of ART, Tanaka et al. simultaneously
incubated ART, BSA, and EDC [15]. However, this
method had the disadvantage that self-coupling of the













Intra-assay (n = 5) 0.1 0.10 ± 0.03 25.5 106.0
0.3 0.30 ± 0.01 3.9 99.0
1.0 1.00 ± 0.02 2.3 99.6
3.0 2.9 ± 0.1 2.9 97.3
10.0 10.1 ± 0.2 2.4 100.8
30.0 29.3 ± 1.7 5.9 97.7
Inter-assay (n = 10) 0.1 0.10 ± 0.02 22.0 103.0
0.3 0.30 ± 0.01 4.3 99.3
1.0 1.00 ± 0.02 2.4 99.9
3.0 3.0 ± 0.1 2.7 98.7
10.0 10.1 ± 0.3 3.2 100.9
30.0 29.2 ± 1.8 6.3 97.2
n number of determinations
aMean ± standard deviation
bCoefficient of variation = 100 × standard deviation/mean
cRecovery (%) = 100 × (mean estimated amounts/added amounts)undesirable self-coupling of BSA or HRP, the NHS ester
method was applied for the conjugation of ART with
BSA or HRP in the present study [18]. The ART-BSA
conjugate as an immunogen of ART was successfully
prepared and used to elicit anti-ART pAbs specific for
ART. Consequently, the anti-ART pAbs and the ART-
HRP conjugate facilitated the development of a direct
competitive ELISA of ART.
The cross-reactivities of the anti-ART pAbs with ARM
and DHA produced in the present study were 0.12 and
0.04 %, respectively, while those with other antimalarial
drugs were less than 0.023 %. These results suggest that
the anti-ART pAbs strongly recognize the entire struc-
ture of the ART molecule. On the other hand, the cross-
reactivities of the anti-ART mAbs produced by Tanaka
et al. and He et al. were 15.9 and 15.5 % with ARM and
4.7 and 8.8 % with DHA [15, 16], respectively. The
present anti-ART pAbs had a higher specificity to ART
than the anti-ART mAbs of either Tanaka et al. or He
et al. Thus, the present assay is considered to be more
specific for the determination of ART than the assay of
Tanaka et al. and Wang et al. [15, 17].
Tanaka et al. showed that the detection limit for ART
in an indirect competitive ELISA using an anti-ART
mAb was around 2 ng/ml [15]. On the other hand, the
present ELISA showed that the detection limit for ART
was 0.1 ng/ml. The present ELISA is clearly more sensi-
tive for the determination of ART concentration than
the indirect ELISA of Tanaka et al. (2007) [15]. In
addition, the recovery of ART in intra- and inter assays
was 97–101 % with less than 7 % of coefficients of vari-
ation in the range of 0.3 to 30 ng/ml. The results dem-
onstrated the precise and accurate of the present ELISA.
Subsequently, the recovery of amounts of ART added
to tablet sample solutions estimated by the ELISA was
validated. The estimated amount of active ART in drug
tablet samples was 38.0 mg (recovery rate 76 %) in the
intra- and inter-assays, which was lower than the 50 mg
expected in the drug tablets (Table 3). The lower estima-
tion is probably affected by various excipients such as
lactose, starch, and cellulose in the drug tablets. How-
ever, the recovery of amounts of ART added to the ART
tablet sample solutions was close to 100 %. The lower
estimation of active ART in the drug tablets is unlikely
due to interference of the excipients. As the assay was
conducted 1 month before the expiry date of the drug
tablets, the lower estimation of active ART in the drug
tablets may be due to degradation and/or loss of active
ART under the conditions of high humidity/high room
temperature during long storage and transport.
Counterfeit or substandard ART drugs have led to
death in malaria patients [7] and allow the selection and
spread of malarial parasites resistant to artemisinin de-
rivatives [8, 21]. Thus, it is important to quantify the
Table 3 Recovery of artesunate (ART) added to tablet sample











0 7.6 ± 0.4 5.2 –
10 17.5 ± 0.8 4.8 99.0
50 56.8 ± 2.3 4.1 98.3
Inter-assay
(n = 12)
0 7.6 ± 0.4 5.1 –
10 18.2 ± 1.3 7.0 105.7
50 57.8 ± 2.2 3.8 100.3
n number of determinations
aMean ± standard deviation, a concentration of 10 ng/ml is equivalent to
50 mg of a tablet sample
bCoefficient of variation = 100 × standard deviation/mean
cRecovery (%) = 100 × (mean ART amounts estimated −mean estimated ART
amounts in a tablet sample solution alone)/ART amounts added
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are currently used to estimate the amount of active ART
[22]. However, the use of methods requiring expensive
equipment and trained technicians is restricted to well-
equipped laboratories and thereafter is unfeasible in
many malaria-endemic areas where quantification of the
amount of ART in tablet samples is needed. By contrast,
the present ELISA method is simple, specific, accurate,
precise, and less time-consuming than the HPLC
methods.
Conclusions
In the present study, the simple and specific ELISA for
quantitative determination of ART was established. The
ELISA method will definitely contribute to not only to
the identification of counterfeit ART drugs but also to
the quantification of the active ART present in the drug
tablets and thus prevent the proliferation of poor quality
ART tablets. Furthermore, the intra- and inter-assay
CVs of the ELISA were less than 10 % in the range of
0.3 to 30 ng/ml with a detection limit of 0.1 ng/ml. The
ELISA allows to accurately measure a low concentration
of ART in biological fluids. Therefore, the ELISA is ap-
plicable for the determination of ART concentrations in
blood and can contribute to pharmacokinetic studies of
the ART in humans and animals.
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